S
Sirnaomics
Biotech & Life Sciences · Gaithersburg, United States · Founded 2007 · IPO 2021
A biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology MoreLess
Sirnaomics Inc. is a biopharmaceutical company that focuses on the discovery and development of RNA interference (RNAi) therapeutics. RNAi is a biological process where RNA molecules inhibit gene expression, effectively silencing targeted genes. This technology is particularly promising for treating various diseases, including cancers and viral infections.
The company primarily serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. Sirnaomics operates in the global biopharmaceutical market, which is characterized by rapid innovation and significant investment in research and development.
Sirnaomics' business model revolves around developing novel RNAi drug candidates and bringing them through clinical trials to market. They also engage in strategic partnerships to enhance their development capabilities. For instance, they have partnered with Precision NanoSystems to develop and manufacture new RNAi drug candidates using advanced technology platforms.
The company generates revenue through several channels. Primarily, they earn money by licensing their RNAi technologies and drug candidates to larger pharmaceutical companies. Additionally, they may receive milestone payments and royalties from these partnerships. Sirnaomics also benefits from grants and funding aimed at advancing medical research.
Recently, Sirnaomics announced the spin-off of RNAimmune, a subsidiary focused on developing mRNA therapeutics and vaccines. This move allows them to diversify their portfolio and tap into the growing market for mRNA-based treatments, which gained significant attention during the COVID-19 pandemic.
In summary, Sirnaomics is a key player in the biopharmaceutical industry, leveraging RNAi technology to develop innovative treatments for serious diseases. Their strategic partnerships and diversified approach position them well for future growth.
Keywords: RNAi therapeutics, biopharmaceutical, gene silencing, cancer treatment, viral infections, clinical trials, mRNA therapeutics, drug development, Precision NanoSystems, RNAimmune.
Company overview
Sirnaomics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2007
- Headquarters
- Gaithersburg, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 61.5
- Investment activity
- 3 companies · latest Jul 2023
- Capital deployed
- $37M
- Preferred round
- Unknown
Valuation & funding
Sirnaomics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $6.4M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Sep 2025 | $17M | — | Bloomage Biotech | ↗ |
| GRANTOther financing | May 2023 | $967K | — | Hong Kong Science & Technology Parks Corporation | ↗ |
| IPOOther financing | Dec 2021 | $50M | $50M | Undisclosed | ↗ |
| SERIES EOther financing | Jul 2021 | $105M | $420M | Rotating Boulder Fund | — |
| SERIES DOther financing | Oct 2020 | Sangel Capital · Longmen Capital · Walvax Biotechnology · River Head Capital | — | ||
| SERIES COther financing | Apr 2019 | Undisclosed | — | ||
| SERIES COther financing | Jan 2019 | Undisclosed | — | ||
| SERIES COther financing | Jun 2018 | Qianhai Shenghui Investment · Sangel Biomedical Venture Capital · HuaKong Equity Investment · Guangzhou YUEXIU Industrial Investment Fund | — | ||
| SERIES BOther financing | Apr 2016 | Value Measured Investment Limited | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$11M | — |
| 2025 | $0 | -100% | −$11M | — |
| 2024 | $1.8M | — | −$31M | -1755.3% |
| 2023 | $0 | — | −$72M | — |
| 2022 | $0 | — | −$93M | — |
| 2021 | $0 | — | −$214M | — |
| 2020 | $0 | — | −$38M | — |
Growth signals
Sirnaomics website traffic
Latest recorded traffic for Sirnaomics is 4.3K monthly website visits, up 65.4% over the last three months. Sirnaomics's team grew 0% over the past year.
Comparisons
Sirnaomics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Sirnaomics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EDIRNAGermantown, United States
→
RNAimmuneGaithersburg, United StatesThe company's focus is on developing treatments and cures for complex diseases using mrna technology
$108Mvaluation
Talent graph
Sirnaomics's talent
Source: Dealroom Talent Intelligence.
Investors
17 investors on Sirnaomics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Sirnaomics has talent and traffic
In the news
Latest news about Sirnaomics
Recent press, funding announcements, and product moves mentioning Sirnaomics — open to read from the original sources.
Market sentiment
What the market is saying about Sirnaomics
An AI-synthesized read of the highest-engagement posts about Sirnaomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sirnaomics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.